Loading…
Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis
The published data on the predictive value of polymorphism of ERCC1 and XPD in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Relevant studies were ident...
Saved in:
| Published in: | Medical oncology (Northwood, London, England) London, England), 2011-03, Vol.28 (1), p.315-321 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c370t-d0854f6d6a10a2f9b54cab69888be0849bdef3b08eb2fa6cc04cd4b59d89a1d53 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c370t-d0854f6d6a10a2f9b54cab69888be0849bdef3b08eb2fa6cc04cd4b59d89a1d53 |
| container_end_page | 321 |
| container_issue | 1 |
| container_start_page | 315 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 28 |
| creator | Wei, Shu-zhen Zhan, Ping Shi, Mei-qi Shi, Yi Qian, Qian Yu, Li-ke Song, Yong |
| description | The published data on the predictive value of polymorphism of ERCC1 and XPD in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Relevant studies were identified by searching the Medline, Embase, CNKI and American Society of Clinical Oncology abstract databases. Inclusion criteria were patients with advanced NSCLC, received platinum-based chemotherapy, evaluation of polymorphism of ERCC1 and XPD and overall response rate (ORR). A total of 12 studies were included in this meta-analysis. For studies evaluating ERCC1 polymorphism at codon 118, the ORR for the wild-type C/C genotype versus the heterozygous C/T and T/T genotype was 2.17 (95% confidence interval (CI), 1.43–3.33;
P
= 0.000). For studies evaluating XPD Asp312Asn and XPD Lys751Gln, the pooled OR was 1.33 (95% CI, 0.92–1.91;
P
= 0.13) and 1.02 (95% CI, 0.72–1.45;
P
= 0.915), respectively. The results indicated that platinum-based chemotherapy sensitivity was significantly associated with polymorphism of ERCC1 C118T. However, XPD Asp312Asn and XPD Lys751Gln were not predictive makers for platinum-based chemotherapy in patients with advanced NSCLC. |
| doi_str_mv | 10.1007/s12032-010-9443-1 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_853996530</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2275807721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-d0854f6d6a10a2f9b54cab69888be0849bdef3b08eb2fa6cc04cd4b59d89a1d53</originalsourceid><addsrcrecordid>eNp1kc1u1TAQhSMEoqXwAGyQxYaVwY7jXJsdupQfqVIrBFJ30cSe9LqKnWAnqfJWPCK-vaWVkLrxWJ7vHM_oFMVrzt5zxjYfEi-ZKCnjjOqqEpQ_KY65lJpywS-f5ruQG8pkzY6KFyldM1ZyWernxVHJeCW4ksfFn4uI1pnJLUgW6GckQ0dOf2y3nECw5PLiMxmHfvVDHHcueeICGWFyGKZEbty0I2AXCAYtCUOgyUPfE4P56OdwRcy-FUlEg25x-WHsszjMnraQssbs0A_TDiOM60cCJK1pQp8RkzWLw5vbITxOQCFAvyaXXhbPOugTvrqrJ8WvL6c_t9_o2fnX79tPZ9SIDZuoZUpWXW1r4AzKTreyMtDWWinVIlOVbi12omUK27KD2hhWGVu1UlulgVspTop3B98xDr9nTFPjXdpvBgGHOTVKCq1rKVgm3_5HXg9zzOPeQrXSldIZ4gfIxCGliF0zRuchrg1nzT7M5hBmk8Ns9mE2PGve3BnPrUd7r_iXXgbKA5ByK1xhfPj5cde_-oytoQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>853689489</pqid></control><display><type>article</type><title>Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis</title><source>Springer Nature</source><creator>Wei, Shu-zhen ; Zhan, Ping ; Shi, Mei-qi ; Shi, Yi ; Qian, Qian ; Yu, Li-ke ; Song, Yong</creator><creatorcontrib>Wei, Shu-zhen ; Zhan, Ping ; Shi, Mei-qi ; Shi, Yi ; Qian, Qian ; Yu, Li-ke ; Song, Yong</creatorcontrib><description>The published data on the predictive value of polymorphism of ERCC1 and XPD in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Relevant studies were identified by searching the Medline, Embase, CNKI and American Society of Clinical Oncology abstract databases. Inclusion criteria were patients with advanced NSCLC, received platinum-based chemotherapy, evaluation of polymorphism of ERCC1 and XPD and overall response rate (ORR). A total of 12 studies were included in this meta-analysis. For studies evaluating ERCC1 polymorphism at codon 118, the ORR for the wild-type C/C genotype versus the heterozygous C/T and T/T genotype was 2.17 (95% confidence interval (CI), 1.43–3.33;
P
= 0.000). For studies evaluating XPD Asp312Asn and XPD Lys751Gln, the pooled OR was 1.33 (95% CI, 0.92–1.91;
P
= 0.13) and 1.02 (95% CI, 0.72–1.45;
P
= 0.915), respectively. The results indicated that platinum-based chemotherapy sensitivity was significantly associated with polymorphism of ERCC1 C118T. However, XPD Asp312Asn and XPD Lys751Gln were not predictive makers for platinum-based chemotherapy in patients with advanced NSCLC.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-010-9443-1</identifier><identifier>PMID: 20143185</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carboplatin - administration & dosage ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Cisplatin - administration & dosage ; DNA-Binding Proteins - genetics ; Endonucleases - genetics ; Hematology ; Humans ; Internal Medicine ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Medicine ; Medicine & Public Health ; Meta-Analysis as Topic ; Oncology ; Original Paper ; Pathology ; Polymorphism, Genetic - genetics ; Prognosis ; Xeroderma Pigmentosum Group D Protein - genetics</subject><ispartof>Medical oncology (Northwood, London, England), 2011-03, Vol.28 (1), p.315-321</ispartof><rights>Springer Science+Business Media, LLC 2010</rights><rights>Springer Science+Business Media, LLC 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c370t-d0854f6d6a10a2f9b54cab69888be0849bdef3b08eb2fa6cc04cd4b59d89a1d53</citedby><cites>FETCH-LOGICAL-c370t-d0854f6d6a10a2f9b54cab69888be0849bdef3b08eb2fa6cc04cd4b59d89a1d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20143185$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wei, Shu-zhen</creatorcontrib><creatorcontrib>Zhan, Ping</creatorcontrib><creatorcontrib>Shi, Mei-qi</creatorcontrib><creatorcontrib>Shi, Yi</creatorcontrib><creatorcontrib>Qian, Qian</creatorcontrib><creatorcontrib>Yu, Li-ke</creatorcontrib><creatorcontrib>Song, Yong</creatorcontrib><title>Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>The published data on the predictive value of polymorphism of ERCC1 and XPD in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Relevant studies were identified by searching the Medline, Embase, CNKI and American Society of Clinical Oncology abstract databases. Inclusion criteria were patients with advanced NSCLC, received platinum-based chemotherapy, evaluation of polymorphism of ERCC1 and XPD and overall response rate (ORR). A total of 12 studies were included in this meta-analysis. For studies evaluating ERCC1 polymorphism at codon 118, the ORR for the wild-type C/C genotype versus the heterozygous C/T and T/T genotype was 2.17 (95% confidence interval (CI), 1.43–3.33;
P
= 0.000). For studies evaluating XPD Asp312Asn and XPD Lys751Gln, the pooled OR was 1.33 (95% CI, 0.92–1.91;
P
= 0.13) and 1.02 (95% CI, 0.72–1.45;
P
= 0.915), respectively. The results indicated that platinum-based chemotherapy sensitivity was significantly associated with polymorphism of ERCC1 C118T. However, XPD Asp312Asn and XPD Lys751Gln were not predictive makers for platinum-based chemotherapy in patients with advanced NSCLC.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Cisplatin - administration & dosage</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Endonucleases - genetics</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-Analysis as Topic</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pathology</subject><subject>Polymorphism, Genetic - genetics</subject><subject>Prognosis</subject><subject>Xeroderma Pigmentosum Group D Protein - genetics</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp1kc1u1TAQhSMEoqXwAGyQxYaVwY7jXJsdupQfqVIrBFJ30cSe9LqKnWAnqfJWPCK-vaWVkLrxWJ7vHM_oFMVrzt5zxjYfEi-ZKCnjjOqqEpQ_KY65lJpywS-f5ruQG8pkzY6KFyldM1ZyWernxVHJeCW4ksfFn4uI1pnJLUgW6GckQ0dOf2y3nECw5PLiMxmHfvVDHHcueeICGWFyGKZEbty0I2AXCAYtCUOgyUPfE4P56OdwRcy-FUlEg25x-WHsszjMnraQssbs0A_TDiOM60cCJK1pQp8RkzWLw5vbITxOQCFAvyaXXhbPOugTvrqrJ8WvL6c_t9_o2fnX79tPZ9SIDZuoZUpWXW1r4AzKTreyMtDWWinVIlOVbi12omUK27KD2hhWGVu1UlulgVspTop3B98xDr9nTFPjXdpvBgGHOTVKCq1rKVgm3_5HXg9zzOPeQrXSldIZ4gfIxCGliF0zRuchrg1nzT7M5hBmk8Ns9mE2PGve3BnPrUd7r_iXXgbKA5ByK1xhfPj5cde_-oytoQ</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Wei, Shu-zhen</creator><creator>Zhan, Ping</creator><creator>Shi, Mei-qi</creator><creator>Shi, Yi</creator><creator>Qian, Qian</creator><creator>Yu, Li-ke</creator><creator>Song, Yong</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20110301</creationdate><title>Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis</title><author>Wei, Shu-zhen ; Zhan, Ping ; Shi, Mei-qi ; Shi, Yi ; Qian, Qian ; Yu, Li-ke ; Song, Yong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-d0854f6d6a10a2f9b54cab69888be0849bdef3b08eb2fa6cc04cd4b59d89a1d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Cisplatin - administration & dosage</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Endonucleases - genetics</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-Analysis as Topic</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pathology</topic><topic>Polymorphism, Genetic - genetics</topic><topic>Prognosis</topic><topic>Xeroderma Pigmentosum Group D Protein - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wei, Shu-zhen</creatorcontrib><creatorcontrib>Zhan, Ping</creatorcontrib><creatorcontrib>Shi, Mei-qi</creatorcontrib><creatorcontrib>Shi, Yi</creatorcontrib><creatorcontrib>Qian, Qian</creatorcontrib><creatorcontrib>Yu, Li-ke</creatorcontrib><creatorcontrib>Song, Yong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wei, Shu-zhen</au><au>Zhan, Ping</au><au>Shi, Mei-qi</au><au>Shi, Yi</au><au>Qian, Qian</au><au>Yu, Li-ke</au><au>Song, Yong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>28</volume><issue>1</issue><spage>315</spage><epage>321</epage><pages>315-321</pages><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>The published data on the predictive value of polymorphism of ERCC1 and XPD in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Relevant studies were identified by searching the Medline, Embase, CNKI and American Society of Clinical Oncology abstract databases. Inclusion criteria were patients with advanced NSCLC, received platinum-based chemotherapy, evaluation of polymorphism of ERCC1 and XPD and overall response rate (ORR). A total of 12 studies were included in this meta-analysis. For studies evaluating ERCC1 polymorphism at codon 118, the ORR for the wild-type C/C genotype versus the heterozygous C/T and T/T genotype was 2.17 (95% confidence interval (CI), 1.43–3.33;
P
= 0.000). For studies evaluating XPD Asp312Asn and XPD Lys751Gln, the pooled OR was 1.33 (95% CI, 0.92–1.91;
P
= 0.13) and 1.02 (95% CI, 0.72–1.45;
P
= 0.915), respectively. The results indicated that platinum-based chemotherapy sensitivity was significantly associated with polymorphism of ERCC1 C118T. However, XPD Asp312Asn and XPD Lys751Gln were not predictive makers for platinum-based chemotherapy in patients with advanced NSCLC.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>20143185</pmid><doi>10.1007/s12032-010-9443-1</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2011-03, Vol.28 (1), p.315-321 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_853996530 |
| source | Springer Nature |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Cisplatin - administration & dosage DNA-Binding Proteins - genetics Endonucleases - genetics Hematology Humans Internal Medicine Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Medicine Medicine & Public Health Meta-Analysis as Topic Oncology Original Paper Pathology Polymorphism, Genetic - genetics Prognosis Xeroderma Pigmentosum Group D Protein - genetics |
| title | Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T20%3A21%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20value%20of%20ERCC1%20and%20XPD%20polymorphism%20in%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer%20receiving%20platinum-based%20chemotherapy:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Wei,%20Shu-zhen&rft.date=2011-03-01&rft.volume=28&rft.issue=1&rft.spage=315&rft.epage=321&rft.pages=315-321&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-010-9443-1&rft_dat=%3Cproquest_cross%3E2275807721%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c370t-d0854f6d6a10a2f9b54cab69888be0849bdef3b08eb2fa6cc04cd4b59d89a1d53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=853689489&rft_id=info:pmid/20143185&rfr_iscdi=true |